



April 20, 2026

Notice Regarding Offer of Refunds to 340B Covered Entities

Alvogen, Inc. (“Alvogen”) has recently determined that, pursuant to 42 U.S.C. §256b(d)(1)(B)(ii) and 42 C.F.R. §10.11(b)(4)), a refund may be due to a 340B Covered Entity which purchased any of the NDCs identified in the table during the noted time periods.

Product Name	NDC-11	Time Period
Sertraline HCl Capsules 150mg 30	47781-0951-30	Sep 24, 2025 - Dec 31, 2025
Sertraline HCl Capsules 200mg 30	47781-0962-30	Sep 24, 2025 - Dec 31, 2025

Alvogen does not believe there were any 340B eligible sales for the aforementioned product(s) and time period. Any 340B Covered Entity that disagrees and believes that they made such purchase(s) at a non-340B price is invited to contact Alvogen at Alvogen-340B-Refunds@Alvogen.com, referencing the NDCs, dates, and purchase quantities with respect to which it believes it was eligible to purchase at the 340B price and thus may be due a refund. Alvogen will review such requests received by December 31, 2026 and issue refunds upon verification.

Alvogen has asked the Health Resources and Services Administration (HRSA) to post this Notice on their public website <https://www.hrsa.gov/opa/manufacture-notice> to ensure transparency to all 340B Covered Entities regarding Alvogen’s 340B ceiling price recalculations and refund process. If you have questions, please contact us at Alvogen-340B-Refunds@Alvogen.com.